Head-to-Head Comparison of Tau and Amyloid Positron Emission Tomography Visual Reads for Differential Diagnosis of Neurodegenerative Disorders : An International, Multicenter Study
(2024) In Annals of Neurology 96(3). p.476-487- Abstract
Objective: We compared the accuracy of amyloid and [18F]Flortaucipir (FTP) tau positron emission tomography (PET) visual reads for distinguishing patients with mild cognitive impairment (MCI) or dementia with fluid biomarker support of Alzheimer's disease (AD). Methods: Participants with FTP-PET, amyloid-PET, and diagnosis of dementia-AD (n = 102), MCI-AD (n = 41), non-AD diseases (n = 76), and controls (n = 20) were included. AD status was determined independent of PET by cerebrospinal fluid or plasma biomarkers. The mean age was 66.9 years, and 44.8% were women. Three readers interpreted scans blindly and independently. Amyloid-PET was classified as positive/negative using tracer-specific criteria. FTP-PET was classified as... (More)
Objective: We compared the accuracy of amyloid and [18F]Flortaucipir (FTP) tau positron emission tomography (PET) visual reads for distinguishing patients with mild cognitive impairment (MCI) or dementia with fluid biomarker support of Alzheimer's disease (AD). Methods: Participants with FTP-PET, amyloid-PET, and diagnosis of dementia-AD (n = 102), MCI-AD (n = 41), non-AD diseases (n = 76), and controls (n = 20) were included. AD status was determined independent of PET by cerebrospinal fluid or plasma biomarkers. The mean age was 66.9 years, and 44.8% were women. Three readers interpreted scans blindly and independently. Amyloid-PET was classified as positive/negative using tracer-specific criteria. FTP-PET was classified as positive with medial temporal lobe (MTL) binding as the minimum uptake indicating AD tau (tau-MTL+), positive with posterolateral temporal or extratemporal cortical binding in an AD-like pattern (tau-CTX+), or negative. The majority of scan interpretations were used to calculate diagnostic accuracy of visual reads in detecting MCI/dementia with fluid biomarker support for AD (MCI/dementia-AD). Results: Sensitivity of amyloid-PET for MCI/dementia-AD was 95.8% (95% confidence interval 91.1–98.4%), which was comparable to tau-CTX+ 92.3% (86.7–96.1%, p = 0.67) and tau-MTL+ 97.2% (93.0–99.2%, p = 0.27). Specificity of amyloid-PET for biomarker-negative healthy and disease controls was 84.4% (75.5–91.0%), which was like tau-CTX+ 88.5% (80.4–94.1%, p = 0.34), and trended toward being higher than tau-MTL+ 75.0% (65.1–83.3%, p = 0.08). Tau-CTX+ had higher specificity than tau-MTL+ (p = 0.0002), but sensitivity was lower (p = 0.02), driven by decreased sensitivity for MCI-AD (80.5% [65.1–91.2] vs. 95.1% [83.5–99.4], p = 0.03). Interpretation: Amyloid- and tau-PET visual reads have similar sensitivity/specificity for detecting AD in cognitively impaired patients. Visual tau-PET interpretations requiring cortical binding outside MTL increase specificity, but lower sensitivity for MCI-AD. ANN NEUROL 2024;96:476–487.
(Less)
- author
- Soleimani-Meigooni, David N.
; Smith, Ruben
LU
; Provost, Karine
; Lesman-Segev, Orit H.
; Allen, Isabel Elaine
; Chen, Miranda K.
; Cho, Hanna
; Edwards, Lauren
; Janelidze, Shorena
LU
; La Joie, Renaud
; Mundada, Nidhi
; Ossenkoppele, Rik
LU
; Stomrud, Erik
LU
; Strandberg, Olof
LU
; Strom, Amelia
; Boxer, Adam L.
; Dage, Jeffrey L.
; Gorno-Tempini, Maria Luisa
; Kramer, Joel H.
; Miller, Bruce L.
; Rojas, Julio C.
; Rosen, Howard J.
; Lyoo, Chul H.
; Hansson, Oskar
LU
and Rabinovici, Gil D.
(Less) - organization
- publishing date
- 2024-09
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Annals of Neurology
- volume
- 96
- issue
- 3
- pages
- 12 pages
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- pmid:38888212
- scopus:85196144225
- ISSN
- 0364-5134
- DOI
- 10.1002/ana.27008
- language
- English
- LU publication?
- yes
- id
- 18a563c4-a513-4791-ae90-197f6a3d67ed
- date added to LUP
- 2024-09-09 15:51:38
- date last changed
- 2024-09-10 03:07:15
@article{18a563c4-a513-4791-ae90-197f6a3d67ed,
abstract = {{<p>Objective: We compared the accuracy of amyloid and [<sup>18</sup>F]Flortaucipir (FTP) tau positron emission tomography (PET) visual reads for distinguishing patients with mild cognitive impairment (MCI) or dementia with fluid biomarker support of Alzheimer's disease (AD). Methods: Participants with FTP-PET, amyloid-PET, and diagnosis of dementia-AD (n = 102), MCI-AD (n = 41), non-AD diseases (n = 76), and controls (n = 20) were included. AD status was determined independent of PET by cerebrospinal fluid or plasma biomarkers. The mean age was 66.9 years, and 44.8% were women. Three readers interpreted scans blindly and independently. Amyloid-PET was classified as positive/negative using tracer-specific criteria. FTP-PET was classified as positive with medial temporal lobe (MTL) binding as the minimum uptake indicating AD tau (tau-MTL+), positive with posterolateral temporal or extratemporal cortical binding in an AD-like pattern (tau-CTX+), or negative. The majority of scan interpretations were used to calculate diagnostic accuracy of visual reads in detecting MCI/dementia with fluid biomarker support for AD (MCI/dementia-AD). Results: Sensitivity of amyloid-PET for MCI/dementia-AD was 95.8% (95% confidence interval 91.1–98.4%), which was comparable to tau-CTX+ 92.3% (86.7–96.1%, p = 0.67) and tau-MTL+ 97.2% (93.0–99.2%, p = 0.27). Specificity of amyloid-PET for biomarker-negative healthy and disease controls was 84.4% (75.5–91.0%), which was like tau-CTX+ 88.5% (80.4–94.1%, p = 0.34), and trended toward being higher than tau-MTL+ 75.0% (65.1–83.3%, p = 0.08). Tau-CTX+ had higher specificity than tau-MTL+ (p = 0.0002), but sensitivity was lower (p = 0.02), driven by decreased sensitivity for MCI-AD (80.5% [65.1–91.2] vs. 95.1% [83.5–99.4], p = 0.03). Interpretation: Amyloid- and tau-PET visual reads have similar sensitivity/specificity for detecting AD in cognitively impaired patients. Visual tau-PET interpretations requiring cortical binding outside MTL increase specificity, but lower sensitivity for MCI-AD. ANN NEUROL 2024;96:476–487.</p>}},
author = {{Soleimani-Meigooni, David N. and Smith, Ruben and Provost, Karine and Lesman-Segev, Orit H. and Allen, Isabel Elaine and Chen, Miranda K. and Cho, Hanna and Edwards, Lauren and Janelidze, Shorena and La Joie, Renaud and Mundada, Nidhi and Ossenkoppele, Rik and Stomrud, Erik and Strandberg, Olof and Strom, Amelia and Boxer, Adam L. and Dage, Jeffrey L. and Gorno-Tempini, Maria Luisa and Kramer, Joel H. and Miller, Bruce L. and Rojas, Julio C. and Rosen, Howard J. and Lyoo, Chul H. and Hansson, Oskar and Rabinovici, Gil D.}},
issn = {{0364-5134}},
language = {{eng}},
number = {{3}},
pages = {{476--487}},
publisher = {{John Wiley & Sons Inc.}},
series = {{Annals of Neurology}},
title = {{Head-to-Head Comparison of Tau and Amyloid Positron Emission Tomography Visual Reads for Differential Diagnosis of Neurodegenerative Disorders : An International, Multicenter Study}},
url = {{http://dx.doi.org/10.1002/ana.27008}},
doi = {{10.1002/ana.27008}},
volume = {{96}},
year = {{2024}},
}